卡莫司汀联合贝伐珠单抗治疗复发高级别胶质瘤的毒性评估
结果显示两组在肝毒性、白细胞减少、淋巴细胞减少、中性粒细胞减少、贫血和血小板减少的发生率或分级上均无显著差异,联合贝伐珠单抗未增加血液学毒性。
要点
- 卡莫司汀联合贝伐珠单抗未增加高级别胶质瘤患者的血液学毒性。
- 3-4级中性粒细胞减少与血小板减少在两组间无显著差异。
- 按卡莫司汀剂量分层后两组毒性差异仍无统计学意义。
核心结论
- 卡莫司汀联合贝伐珠单抗与单药卡莫司汀相比,未增加血液学毒性的发生率或分级。
主要发现
- 两组在肝毒性、白细胞减少、淋巴细胞减少、中性粒细胞减少、贫血和血小板减少的发生率或分级上无显著差异。
- 单药组与联合组3-4级中性粒细胞减少发生率分别为20%与13.8%(p=0.55),3-4级血小板减少发生率分别为23.3%与23.8%(p=1)。
- 按卡莫司汀剂量(<150 mg/m2、150 mg/m2、>150 mg/m2)分层后,两组3-4级中性粒细胞减少或血小板减少仍无统计学显著差异。
临床怎么用
- 对于复发或进展性高级别胶质瘤患者,卡莫司汀联合贝伐珠单抗未显示增加血液学毒性,可作为毒性监测的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: An increased incidence in hematologic toxicity has been reported with the addition of bevacizumab to lomustine for patients with recurrent or progressive high grade gliomas (HGG). Data regarding incidence of toxicity with combination bevacizumab and carmustine is limited. The purpose of this study is to compare toxicity of single agent carmustine and carmustine plus bevacizumab for patients with HGGs. METHODS: This single center retrospective study at Memorial Sloan Kettering Cancer Center included pathologically confirmed HGG with age ≥ 18 years who received carmustine between January 2003 and May 2017. RESULTS: Sixty-five patients with HGGs collectively received 110 doses of BCNU during the specified time period. Sixteen patients received single agent BCNU (30 doses); 49 patients received combination bevacizumab with BCNU (80 doses). There was no significant difference in incidence or grade of toxicity between single agent and combination therapy with respect to hepatotoxicity, leukopenia, lymphopenia, neutropenia, anemia, and thrombocytopenia. Rates of grade 3 and 4 neutropenia (20% vs 13.8%, p = 0.55) and thrombocytopenia (23.3% vs 23.8%, p = 1) did not differ between single agent BCNU versus combination therapy. When stratified based on dose ( < 150 mg/m2, 150 mg/m2, > 150 mg/m2), there was no statistically significant difference between the two groups with respect to grade 3 and 4 neutropenia or thrombocytopenia. CONCLUSIONS: This is the first study to report the toxicity of carmustine with or without bevacizumab for the treatment of recurrent and refractory HGG. The addition of bevacizumab to carmustine did not increase incidence or grade of hematologic toxicity when compared to single agent carmustine.
引用
- Yerram P, Reiss SN, Modelevsky L, et al. Evaluation of toxicity of carmustine with or without bevacizumab in patients with recurrent or progressive high grade gliomas. J Neurooncol. 2019. PMID: 31432377. doi:10.1007/s11060-019-03266-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。